摘要Background Ertapenem has been demonstrated to be highly effective for the treatment of complicated infections. Theaim of this study was to compare the efficacy and safety of ertapenem with ceftriaxone.
1Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993; 329: 1328-1334.
2Sawyer MD, Dunn DL. Antimicrobial therapy of intra-abdomi- nal sepsis. Infect Dis Clin North Am 1992; 6: 545-570.
3Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/ American Thoracic Society Consensus Guidelines on the man- agement of community-acquired pneumonia in adults. Clin In- fect Dis 2007; 44: S27-S72.
4Solomkin JS, Mazuski JE, Baron E J, Sawyer RG, Nathens AB, DiPiro JT, et al. Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections. Clin Infect Dis 2003; 37: 997-1005.
5Bouchillon SK, Johnson BM, Hoban D J, Johnson JL, Dowzicky M J, Wu DH, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin- resistant Enterococcus faecium and methicillin-resistant Staphy- lococcus aureus in 38 centres from 17 countries: the PEARLS Study 2001-2002. Int J Antimicrob Agents 2004; 24:19-124.
6Winokur PL, Canton R, Casellas JM, Legakis N. Variation in the prevalence of strains expressing an extended-spectrum beta-lac- tamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Infect Dis 2001; 32: S94-S103.
7Kaye KS, Engemann J J, Fraimow HS, Abrutyn E. Pathogens re- sistant to antimicrobial agents: epidemiology, molecular mecha- nisms and clinical management. Infect Dis Clin North Am 2004; 18:467-511.
8Shah PM, Isaacs RD. Ertapenem, the first of a new group of car- bapenems. J Antimicrob Chemother 2003; 52: 538-542.
9Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Moni- toring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 965-973.
10Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001 ; 45: 1915-1918.
